Genome&Company Q3 revenue KRW 7.2 billion, loss from main business KRW 7.5 billion
AI summary · Not investment advice
Genome & Company sold KRW 7.2 billion in Q3 and lost KRW 7.5 billion from its main business; sales rose 10.4% from a year earlier and 15.8% from the prior quarter.
Operating profit · 3 months
KRW -7.5 billion
Key facts
- Revenue (3 months)
- KRW 7.2 billion
- Net income (3 months)
- KRW -8.4 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 6.6 billion
- Revenue (year to date)
- KRW 19.3 billion
- Operating profit (prior-year 3 months)
- KRW -8.1 billion
- Operating profit (year to date)
- KRW -21.5 billion
- Net income (prior-year 3 months)
- KRW -8.0 billion
- Net income (year to date)
- KRW -57.9 billion
Commentary
AI commentary · Not investment advice
What happened
Genome & Company filed its quarterly report on a consolidated basis for the third quarter. Sales for the latest 3 months were KRW 7,238,987,085. Sales for the same 3 months a year earlier were KRW 6,557,558,334.
In the company's terms
Operating profit (profit from the core business) for the latest 3 months was a loss of KRW 7,454,269,238. A year earlier it was a loss of KRW 8,089,713,959. Net income (final profit after taxes and other costs) for the latest 3 months was a loss of KRW 8,429,516,400. A year earlier it was a loss of KRW 8,043,803,904.
What changes for shareholders
For the year to date, sales were KRW 19,275,010,167. Operating profit was a loss of KRW 21,523,834,838. Net income was a loss of KRW 57,888,402,904.
Sales for the latest 3 months rose 10.4% from a year earlier. They rose 15.8% from the previous quarter.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
G